Biotech News
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
MLYS (MLYS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.
The source domain is mlys.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.
The original release is available below in a new tab so readers can continue into the full source when needed.